OBJECTIVE—Cooling detection threshold testing may be an important quantitative method for assessing polyneuropathy, in that it has traditionally been viewed as a measure of small-fiber involvement. The present study sought to determine the agreement between two common testing devices and to determine whether these are concordant in their association with predictor variables for diabetic sensory polyneuropathy.

RESEARCH DESIGN AND METHODS—A total of 83 patients with diabetes (10 patients with type 1 diabetes and 73 patients with type 2 diabetes) and a wide spectrum of diabetic sensory polyneuropathy severity underwent concurrent cooling detection threshold testing using the Medoc and CASE IV instruments. Common predictor variables for diabetic sensory polyneuropathy were measured on the same day.

RESULTS—Measurements of cooling detection thresholds by both instruments were highly correlated (Spearman’s correlation coefficient 0.81, P < 0.001) and demonstrated a high degree of agreement by the method of Bland and Altman (95% distribution critical values for the difference in cooling detection thresholds, +7.5 and −5.6°C). Cooling detection thresholds by both instruments were strongly correlated with clinical indicators of large-fiber neuropathy but not with the symptoms of small-fiber neuropathy (pain).

CONCLUSIONS—These two instruments available for assessment of cooling detection thresholds are interchangeable for research in diabetic sensory polyneuropathy. However, this modality is equivalent to other modalities of quantitative sensory threshold testing in its association with indicators of large-fiber neuropathy and does not seem to provide an advantage for the prediction of small-fiber involvement.

Quantitative sensory threshold testing is an important noninvasive tool for the investigation of diabetic sensory polyneuropathy and, as a consequence, is commonly used in clinical trials (15). Quantitative sensory threshold tests are capable of assessing individual sensory modalities, including the perception thresholds for vibration and thermal stimuli. A number of different devices are used in clinical practice and in research, but the manner in which results from these devices relate to each other for a given modality is frequently speculative.

Vibration perception threshold testing is the quantitative modality most commonly used for assessment of diabetic sensory polyneuropathy. Results are believed to represent large fiber sensory nerve function because of evidence for strong associations with sural nerve action potential amplitude (6) and with clinical measures of large fiber function (7). For this modality, it has also been demonstrated that two different devices displayed strong correlation and agreement with each other in the measurement of vibration perception thresholds (7). However, for thermal detection thresholds, the different devices have not been systematically compared (4, 810). This is of paramount importance, in that thermal detection thresholds (cold and heat detection) have the major theoretical advantage of specifically representing small- fiber sensory nerve function (11,12). Studies that aim to explore the natural history and potential treatment of small- fiber neuropathy using thermal detection threshold testing must ensure that the available devices are measuring the same biology of nerve function and structure. In this regard, it is essential to establish whether assumptions made about nerve structure and function from one device are generalizable to another device.

To test this issue, we assessed the correlation and agreement between cooling detection thresholds obtained at the same anatomic site in patients with diabetic sensory polyneuropathy using the two common testing devices: the Medoc instrument and the CASE IV instrument.

The study was conducted at the Toronto General Hospital/University Health Network (TGH/UHN) in the Diabetic Neuropathy Research Clinic from June 2002 to January 2003. Approval from the University Health Network Research Ethics Board was obtained, and written informed consent was documented for each participant.

A total of 94 consecutive patients attending the University Health Network Diabetic Neuropathy Research Clinic were identified and categorized using the Toronto Clinical Neuropathy Score (13) (Table 1). The Toronto Clinical Neuropathy Score was used to stratify patients into three groups of diabetic sensory polyneuropathy severity: 6–8 indicated mild neuropathy, 9–11 indicated moderate neuropathy, and ≥12 indicated severe neuropathy. Study accrual was terminated when the smallest group consisted of 25 study subjects. A total of 83 participants were considered for analysis because they completed the cooling detection threshold testing component of the study protocol. All patients first underwent a comprehensive medical and neurologic evaluation to exclude neuropathy secondary to etiologies other than diabetic sensory polyneuropathy (e.g., alcohol, uremia, nutritional deficiency, toxins, familial neuropathy). The clinical characteristics of the 11 patients who did not complete the protocol did not differ significantly from those of the 83 participants (data not shown).

Study protocol

Cooling detection thresholds were obtained on the dorsum of the left foot using the Medoc TSA-II NeuroSensory Analyzer (Ramat-Yishai, Israel) and the CASE IV instrument (WR Electronics, Minneapolis, MN). Cooling detection threshold testing was performed on each patient using both the Medoc and CASE IV devices using a random selection of the order of testing. The stimulus was applied to the dorsum of the left foot, and both devices were used during the same clinical visit within a 4-h interval. To eliminate observer bias, a different technician operated each device for each patient.

The Medoc device used a method of limits (9). The stimulator was applied to the dorsum of the foot at a temperature of 32°C, and the temperature was gradually decreased to the first level detected by the patient as a cooler stimulus than the preceding. Five trials were performed, and a catch trial, with null stimulus, was inserted randomly during testing. An average of the five levels was taken.

Testing with the CASE IV device was performed using the 4-2-1 testing algorithm (14). The stimulator was applied to the dorsum of the left foot. The stimulus range was in 25 preprogrammed steps from 0 (no stimulus/warmest temperature) to 25 (maximum stimulus/coldest temperature). The starting point for testing was at point 13 (midpoint of the range), which was at a preset baseline temperature of 30°C. If the patient perceived the stimulus as cold, then the temperature was increased by four steps. If still perceived as cold, then the temperature was increased by another four steps. If the stimulus was not perceived as cold at the higher temperature, then the temperature was lowered by two steps. If perceived as cold, it was increased by one step. When the patient could not distinguish between two levels separated by the lowest step of 1, then that level was defined as the just-noticeable-difference (JND) for cooling perception. Reproducibility has previously been demonstrated to be very good for cooling detection thresholds in the lower extremity by both instruments (15,16).

The CASE IV instrument does not detect cooling thresholds <9°C. To compare cooling detected at lower temperatures, an arbitrary value of 0°C was assigned for any CASE IV result of a cooling detection threshold of ≤9°C. The Medoc device can detect a cooling detection threshold as low as 0°C.

The assessment of predictor variables was conducted on the same day as the cooling detection threshold measurements. Pain assessment was determined using an 11-point Likert visual analog scale of the modified short form McGill pain questionnaire (17). Monofilament testing and nerve conduction studies of the lower limbs were each conducted separately by an individual masked to the results of all other testing. Monofilament testing was conducted to determine the number of insensate responses out of eight applications to the dorsum of the great toe bilaterally. Although a number of different techniques for monofilament testing exist, this technique has been validated as a reliable screening test for the diagnosis of diabetic neuropathy (18). Quantitative measurement of vibration perception threshold was performed with the Medoc device using the method of limits (9). Nerve conduction studies were conducted with Keypoint electrophysiology equipment (Medtronic, Mississauga, Ontario, Canada) using standardized testing of the left sural sensory nerves for signal amplitude, and temperature was maintained at >31°C in the lower extremities.

Statistical analysis

Descriptive statistics and linear regression were performed in SAS (version 8.02 for Windows; SAS Institute, Cary, NC). Agreement of the cooling detection thresholds (in °C) obtained with the two instruments was compared by the method of Bland and Altman (19, 20). Correlation was analyzed using Spearman’s correlation coefficients for all comparisons, including analysis of the correlation between cooling detection thresholds and vibration perception thresholds with sural nerve sensory amplitudes. All predictor variables for the univariate linear regression models with the cooling detection threshold as dependent variable were continuous, and the linearity assumptions were confirmed by standard regression diagnostics.

A total of 83 patients were enrolled in the study. The clinical characteristics are shown in Table 2. Most patients had type 2 diabetes, and the mean duration of diabetes was 10 years. Patients had a wide spectrum of diabetic sensory polyneuropathy severity and, overall, had a moderate degree of diabetic neuropathy as determined by the Toronto Clinical Neuropathy Score (mean score 10.1 ± 8.0 out of 19).

Cooling detection thresholds obtained with the Medoc instrument strongly correlate with those obtained from the CASE IV (Spearman’s correlation coefficient 0.81, P < 0.001; Fig. 1). The plotted regression line in Fig. 1 approximates the line of equality (slope of 1), and therefore no systematic bias is observed.

To further explore agreement between the variables, the statistical method of Bland and Altman (19,20) was performed. Figure 2 demonstrates the difference between cooling detection thresholds (CASE IV threshold minus Medoc threshold) plotted against the average cooling detection threshold for the two devices. Figure 2 shows very good agreement between cooling detection threshold measurements by the two devices across the full range of average values (Fig. 2). No change in the pattern seen in Fig. 2 was noted when the analysis was repeated with log-transformed values (data not shown).

Although a strong correlation between the CASE IV and Medoc instruments was observed, we aimed to confirm that the two instruments measured the same aspects of nerve structure or function by pursuing an analysis of common determinants for diabetic sensory polyneuropathy (Table 3). We hypothesized that if an association with such a risk factor was discordant between the CASE IV and the Medoc instruments, then this may indicate that the machines are not measuring the same aspects of nerve fiber biology. Clinical parameters (duration of diabetes and the Toronto Clinical Neuropathy Score), physical examination maneuvers (the monofilament score), and electrophysiologic parameters (sural nerve sensory amplitude) were all strongly associated with cooling detection threshold measured by both instruments (Table 3). Pain symptoms, traditionally believed to be a sensory modality mediated by small nerve fibers (11,12,21) were not predictive of cooling detection thresholds using either instrument. Sural nerve amplitude, a reliable marker of large sensory fiber function, had the strongest association with cooling detection thresholds (Spearman’s correlation coefficients −0.64, P < 0.001, and −0.62, P < 0.001, for the Medoc and CASE IV devices, respectively). Vibration perception threshold testing, a modality mediated by large sensory fibers, correlated strongly with sural nerve amplitude (Spearman’s correlation coefficient −0.61, P < 0.001).

Both the CASE IV and Medoc protocols were tolerated well by all patients, and there were no reports of discomfort associated with either instrument.

Quantitative sensory threshold testing is an important, noninvasive tool used to quantitate the extent of peripheral nerve injury. It has become a useful parameter in clinical trials for patients with diabetic sensory polyneuropathy. Although it is assumed that different devices reliably measure the same modality, agreement between the devices must be demonstrated before comparisons can be made between studies.

Strong correlation and agreement were observed for cooling detection thresholds using the two devices in this study. The agreement was maintained across the full range of values, indicating that the severity of diabetic sensory polyneuropathy did not influence the consistency of measurement by each device. In addition, clinical parameters known to predict diabetic sensory polyneuropathy correlated strongly and concordantly with cooling detection thresholds measured by both devices. From this level of agreement and concordance, we can confidently infer that the Medoc and CASE IV devices are representing the same sensory pathways. Whether these pathways involve large fibers exclusively or a combination of small and large fibers is a question for further study. The results of research studies that investigate the role of cooling detection thresholds to characterize the nature of diabetic sensory polyneuropathy can therefore be directly compared regardless of whether the CASE IV or the Medoc instruments are used.

Although also associated with large fiber injury (21,22), pain sensation is believed to be a sensory modality mediated primarily by small-caliber nerve fibers. In this study, no correlation was demonstrated between cooling detection thresholds and pain scores measured by a quantitative visual analog scale. Although pain has traditionally been regarded as a manifestation of small-fiber function, this study is consistent with other cross-sectional (23) and prospective (24) studies in demonstrating a discordance between pain scores and small-fiber neuropathy. Supportive evidence for pain as a predictor of small-fiber structure and function remains to be demonstrated. In a recent study of nerve fiber morphology (25), a cohort of patients diagnosed with idiopathic painful small-fiber neuropathy underwent cooling detection threshold testing, nerve conduction studies, and intra-epidermal nerve fiber analysis of skin biopsy. The latter is regarded as the reference standard for the identification of small-fiber neuropathies. Intra-epidermal nerve fiber density was abnormal in 90% of patients, whereas only 60% of patients had abnormal cooling detection thresholds. Electrophysiology and vibration perception thresholds were abnormal in a significant proportion of patients with morphologic evidence for small-fiber neuropathy, indicating that large-fiber damage was present in a significant proportion despite a clinical presentation that suggested exclusive small-fiber neuropathy.

Nerve conduction studies remain the most reliable, accurate, and sensitive measure of peripheral nerve function (26). However, the technique assesses the function of large-caliber nerve fibers exclusively. It has been shown that vibration perception threshold testing using two different instruments correlated strongly with sural nerve action potential amplitudes over a wide range of diabetic sensory polyneuropathy severity (7). Akin to vibration perception thresholds, the current study has demonstrated that cooling detection thresholds are an alternate quantitative sensory threshold marker for the degree of large-fiber neuropathy as measured by sural nerve amplitudes. This finding is consistent with a study of thermal and vibration perception thresholds in the diagnosis of diabetic sensory polyneuropathy (27). Current data suggest that an intimate association exists between large- and small-fiber damage in diabetic sensory polyneuropathy and that these separate functional or structural disturbances cannot be distinguished using quantitative sensory testing in this patient population.

This study demonstrates that two cooling detection threshold instruments, the Medoc and CASE IV, have strong correlation and quantitative agreement and are representing the same underlying nerve pathology. Although both devices can be used for clinical or research purposes, the Medoc device may be favored in studies of moderate and severe diabetic sensory polyneuropathy because it is able to quantitate cooling detection thresholds at lower temperature ranges (below 9°C) than the CASE IV instrument. In terms of the validity of cooling detection thresholds in representing the nature of nerve fiber involvement, this study failed to intimate a relationship between cooling detection thresholds and small-fiber neuropathy. Instead, cooling detection thresholds behave as reliably as vibration perception thresholds in their association with markers of large-fiber neuropathy in diabetes patients. All evidence taken together, it seems that small-fiber neuropathy is not mutually exclusive from large fiber involvement, and abnormality in the structure of small nerve fibers does not reliably predict functional deficits in these fibers in patients with diabetes. Future studies of quantitative sensory threshold testing and small-fiber morphology are required to define the role of small-fiber neuropathy in diabetic sensory polyneuropathy.

Figure 1—

Correlation (Spearman’s correlation coefficient 0.81, P < 0.001) between cooling detection thresholds obtained by the Medoc and CASE IV protocols in the 83 participants with diabetes. The CASE IV instrument does not quantitate cooling detection threshold ≤9°C. Values between 0 and 9° for this instrument were assigned a value of zero (see research design and methods for details).

Figure 1—

Correlation (Spearman’s correlation coefficient 0.81, P < 0.001) between cooling detection thresholds obtained by the Medoc and CASE IV protocols in the 83 participants with diabetes. The CASE IV instrument does not quantitate cooling detection threshold ≤9°C. Values between 0 and 9° for this instrument were assigned a value of zero (see research design and methods for details).

Close modal
Figure 2—

Agreement [difference plotted against the mean of the cooling detection threshold in oC by the two methods; this comparison is according to the method of Bland and Altman (19,20) described in research design and methods] between cooling detection thresholds obtained by the Medoc and CASE IV protocols in the 83 participants with diabetes. The dashed lines represent the upper and lower critical values for the 95% distribution in the difference between the cooling detection threshold obtained by the two methods (threshold obtained by the Case IV instrument minus that obtained by the Medoc instrument). There is very good agreement across the full range of average values, such that the upper critical value is a difference of +7.5°C and the lower critical value is a difference of −5.6°C. Bias is minimal, such that the mean difference is +1.4°C for the Case IV instrument minus that obtained by the Medoc instrument.

Figure 2—

Agreement [difference plotted against the mean of the cooling detection threshold in oC by the two methods; this comparison is according to the method of Bland and Altman (19,20) described in research design and methods] between cooling detection thresholds obtained by the Medoc and CASE IV protocols in the 83 participants with diabetes. The dashed lines represent the upper and lower critical values for the 95% distribution in the difference between the cooling detection threshold obtained by the two methods (threshold obtained by the Case IV instrument minus that obtained by the Medoc instrument). There is very good agreement across the full range of average values, such that the upper critical value is a difference of +7.5°C and the lower critical value is a difference of −5.6°C. Bias is minimal, such that the mean difference is +1.4°C for the Case IV instrument minus that obtained by the Medoc instrument.

Close modal
Table 1—

Clinical stratification method using the Toronto Clinical Neuropathy Score

Symptom scoresReflex scoresSensory test scores
Foot pain Knee reflexes Pinprick 
Numbness Ankle reflexes Temperature 
Tingling  Light touch 
Weakness  Vibration 
Ataxia  Position sense 
Upper limb symptoms   
Symptom scoresReflex scoresSensory test scores
Foot pain Knee reflexes Pinprick 
Numbness Ankle reflexes Temperature 
Tingling  Light touch 
Weakness  Vibration 
Ataxia  Position sense 
Upper limb symptoms   

Symptom scores were graded as present = 1, absent = 0 (numbness, tingling as perceived at toes and in feet). Reflex scores were graded as absent = 2, reduced = 1, normal = 0 for each side. Sensory test scores were graded as abnormal = 1, normal = 0. Maximum possible score was 19. The score was used to stratify patients into three groups of severity: 6–8 indicated mild neuropathy, 9–11 indicated moderate neuropathy, and ≥12 indicated severe neuropathy.

Table 2—

Clinical characteristics of the 83 study participants with diabetes

Clinical characteristicValue
Sex  
 Men 53 (64) 
 Women 30 (36) 
Age (years) 57.9 ± 9.7 
Diabetes  
 Type 1 diabetes 10 (12) 
 Type 2 diabetes 73 (88) 
Duration of diabetes (years) 10.1 ± 8.0 
Duration of neuropathy (years) 3.3 ± 3.7 
Neuropathy grade*  
 Mild 32 (39) 
 Moderate 26 (31) 
 Severe 25 (30) 
HbA1c (%) 7.6 ± 2.2% 
Clinical characteristicValue
Sex  
 Men 53 (64) 
 Women 30 (36) 
Age (years) 57.9 ± 9.7 
Diabetes  
 Type 1 diabetes 10 (12) 
 Type 2 diabetes 73 (88) 
Duration of diabetes (years) 10.1 ± 8.0 
Duration of neuropathy (years) 3.3 ± 3.7 
Neuropathy grade*  
 Mild 32 (39) 
 Moderate 26 (31) 
 Severe 25 (30) 
HbA1c (%) 7.6 ± 2.2% 

Data are n (%) or means ± SD. *According to the grading system derived from the Toronto Clinical Neuropathy Score (see research design and methods section for full details).

Table 3—

Univariate association of selected predictor variables on cooling detection thresholds obtained by CASE IV and the Medoc instruments

VariableCASE IV
Medoc
Unadjusted parameter estimate (β)*PUnadjusted parameter estimate (β)*P
Age (years) 0.07 0.51 0.03 0.78 
Duration of diabetes (years) −0.45 <0.001 −0.43 0.001 
Pain score −0.01 0.98 −0.18 0.76 
Toronto Clinical Neuropathy Score −1.47 <0.001 −1.46 <0.001 
Monofilament score§ −1.6 <0.001 −1.8 <0.001 
Sural amplitude 0.97 <0.001 1.10 <0.001 
Vibration perception (μm) −0.19 <0.001 −0.22 <0.001 
VariableCASE IV
Medoc
Unadjusted parameter estimate (β)*PUnadjusted parameter estimate (β)*P
Age (years) 0.07 0.51 0.03 0.78 
Duration of diabetes (years) −0.45 <0.001 −0.43 0.001 
Pain score −0.01 0.98 −0.18 0.76 
Toronto Clinical Neuropathy Score −1.47 <0.001 −1.46 <0.001 
Monofilament score§ −1.6 <0.001 −1.8 <0.001 
Sural amplitude 0.97 <0.001 1.10 <0.001 
Vibration perception (μm) −0.19 <0.001 −0.22 <0.001 

Univariate associations with cooling detection thresholds were remarkably concordant between the two methods of measurement. The relationships between HbA1c and the cooling detection threshold measured by the CASE IV and Medoc instruments were strong (unadjusted β-coefficient of −0.65 (P = 0.21) and −0.94 (P = 0.07, respectively), but measurements were unavailable for 31 of the 83 participants for this variable.

*

Parameter estimates are for the linear regression of the continuous variables on cooling detection threshold in oC. For example, every increase in duration of diabetes by 1 year is associated with a mean decrease in the cooling detection threshold of 0.45oC for the Case IV instrument and 0.43oC for the Medoc instrument;

the pain score is derived from a visual analog scale as described in the research design and methods section and varies between 0 (no limb pain) and 10 (maximal limb pain);

aggregate score of symptoms and signs described in research design and methods section. The total score ranges from 0 (no neuropathy) to 19 (severe neuropathy);

§

The number of insensate responses out of eight applications of the monofilament to the dorsum of the great toe bilaterally;

the sensory amplitude potentials in the sural nerve of the left leg by electrophysiologic methods (μV).

We thank S. Gogov, D. Liang, E. Ng, M. Ngo, K. Nwe, F. Paiz, and S. Zhou for their involvement in implementation and data management.

1
Kahn R: Proceedings of a consensus development conference on standardized measures in diabetic neuropathy: quantitative sensory testing.
Diabetes Care
15
:
1092
–1094,
1992
2
Maser R, Nielsen V, Bass E, Manjoo Q, Dorman JS, Kelsey SF, Becker DJ, Orchard TJ: Measuring diabetic neuropathy: assessment and comparison of clinical examination and quantitative sensory testing.
Diabetes Care
12
:
270
–275,
1989
3
Bril V: Peripheral neuropathies: experience in large multicentre trials. In
Clinical Trials in Neurology
. Guiloff R, Ed. London, Springer-Verlag,
2001
, p.
479
–484
4
Dyck P, Bushek W, Spring E, Karnes J, Litchy WJ, O’Brien PC, Service FJ: Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy.
Diabetes Care
10
:
432
–440,
1987
5
Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.
Diabetologia
36
:
150
–154,
1993
6
Bril V, Kojic J, Ngo M, Clark K: Comparison of the Neurothesiometer and Vibratron in measuring vibration perception threshold and relationship to nerve conduction studies.
Diabetes Care
20
:
1360
–1362,
1997
7
Bril V, Perkins B: Comparison of vibration thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies.
Diabet Med
19
:
661
–666,
2002
8
Arezzo J, Schaumburg H, Laudadio C: Thermal sensitivity tester: device for quantitative assessment of thermal sense in diabetic neuropathy.
Diabetes
35
:
590
–592,
1986
9
Yarnitsky D: Quantitative sensory testing.
Muscle Nerve
20
:
198
–204,
1997
10
Redmond JM, McKenna MJ, Feingold M, Ahmad BK: Sensory testing versus nerve conduction velocity in diabetic polyneuropathy.
Muscle Nerve
15
:
1334
–1339,
1992
11
Gruener G, Dyck PJ: Quantitative sensory testing: methodology applications and future directions.
J Clin Neurophysiol
11
:
568
–583,
1994
12
Suarez GA, Dyck PJ: Quantitative sensory assessment. In
Diabetic Neuropathy
. 2nd ed. Dyck PJ, Thomas PK, Eds. Philadelphia, WB Saunders,
1999
, p.
151
–169
13
Bril V, Perkins BA: Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy.
Diabetes Care
25
:
2048
–2052,
2002
14
Dyck PJ, O’Brien PC, Kosanke JL, Gillen DA, Karnes JL: A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold.
Neurology
43
:
1508
–1512,
1993
15
Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ 3rd, O’Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA: The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.
Neurology
41
:
799
–807,
1991
16
Yarnitsky D, Sprecher E: Thermal testing: normative data and repeatability for various test algorithms.
J Neurol Sci
125
:
39
–45,
1994
17
Melzack R: Short-form McGill pain questionnaire.
Pain
30
:
191
–197,
1987
18
Perkins BA, Olaleye D, Zinman B, Bril V: Simple screening tests for peripheral neuropathy in the diabetes clinic.
Diabetes Care
24
:
250
–256,
2001
19
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement.
Lancet
i
:
307
–310,
1986
20
Bland JM, Altman DG: Comparing methods of measurement: why plotting differences against standard method is misleading.
Lancet
346
:
1085
–1087,
1995
21
Lacomis D: Small-fiber neuropathy.
Muscle Nerve
26
:
173
–188,
2002
22
Dyck PJ, Lambert EH, O’Brien PC: Pain in peripheral neuropathy related to rate and kind of fiber degeneration.
Neurology
26
:
466
–471,
1976
23
Britland ST, Young RJ, Sharma AK, Clarke BF: Acute and remitting painful diabetic polyneuropathy: a comparison of peripheral nerve fiber pathology.
Pain
48
:
361
–370,
1992
24
Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G: A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy.
Diabet Med
11
:
17
–21,
1994
25
Jaradeh S, Peltier W, Barboi A, Yellick M, Ho H: Idiopathic painful small-fiber neuropathies: a prospective study of 30 patients (Abstract).
J Peripheral Nervous System
8
:
26
,
2003
26
Nasseri K, Strijers RLM, Dekhuijzen LS, Buster M, Bertelsmann FW: Reproducibility of different methods for diagnosing and monitoring diabetic neuropathy.
Electromyogr Clin Neurophysiol
38
:
295
–299,
1998
27
Vinik AI, Suwanwalaikorn S, Stansberry KB, Holland MT, McNitt PM, Colen LE: Quantitative measurement of cutaneous perception in diabetic neuropathy.
Muscle Nerve
18
:
574
–585,
1995

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.